Dulaglutide shows consistent efficacy in reducing HbA1c, body weight in T2D patients
The glucagon-like peptide-1 (GLP-1) receptor agonist (RA) dulaglutide shows highly consistent effectiveness on glycated haemoglobin (HbA1c) and body weight reduction in patients with type 2 diabetes (T2D), reveals a study. Its effectiveness remains significant even in subgroups of patients poorly represented in randomized controlled trials (RCTs).
Dulaglutide shows consistent efficacy in reducing HbA1c, body weight in T2D patients
03 Jun 2020